FOLFOX regimen: Clinical Trials

11 trials of FOLFOX regimen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 withdrawn, 1 not yet recruiting, 1 recruiting. 11 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Completed 7, Withdrawn 2, Not yet recruiting 1, Recruiting 1
Phase 23Completed 2, Not yet recruiting 1

Follow FOLFOX regimen: new trials by email Literature Review of FOLFOX regimen trials Research Report on FOLFOX regimen

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma
Phase 1 / Phase 2Not yet recruitingBinYong Liang1002026-04-302026-04-13
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
M3T01, Pembrolizumab, Chemoradiation - Advanced Solid Tumors
Phase 1RecruitingProvidence Health & Services1102025-06-172026-07-23
Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy
Regorafenib, Nivolumab, CapeOX - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Phase 1 / Phase 2CompletedNational Cancer Center Hospital East302022-06-062026-04-09
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
Entinostat, FOLFOX regimen - Pancreas Cancer
Phase 1WithdrawnAbramson Cancer Center at Penn Medicine2021-01-012021-01-15
Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy
FOLFOX regimen, Nivolumab, Ipilimumab - Colorectal Cancer Metastatic
Phase 1WithdrawnGustave Roussy, Cancer Campus, Grand Paris2019-06-042020-02-17
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
ompenaclid, FOLFIRI, Bevacizumab - Gastrointestinal Cancer, Gastrointestinal Neoplasms
Phase 1CompletedInspirna, Inc.892018-06-052025-04-03
Lidocaine for Oxaliplatin-induced Neuropathy
Lidocaine Hydrochloride, Placebo, FOLFOX regimen - Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy
Phase 1 / Phase 2CompletedWashington University School of Medicine262017-09-152022-03-09
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
FOLFOX regimen, bevacizumab, dulanermin - Metastatic Colorectal Cancer
Phase 1CompletedGenentech, Inc.232009-05-012016-11-02
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
bevacizumab, FOLFOX regimen, fluorouracil - Colorectal Cancer
Phase 1CompletedCity of Hope Medical Center112009-03-112025-06-22
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
FOLFOX regimen, dexamethasone, floxuridine - Colorectal Cancer, Metastatic Cancer
Phase 1CompletedMemorial Sloan Kettering Cancer Center382003-01-012025-03-26
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
FOLFOX regimen, dexamethasone, floxuridine - Colorectal Cancer, Metastatic Cancer
Phase 1CompletedMemorial Sloan Kettering Cancer Center2000-08-012013-01-18

Conditions studied

Colorectal Neoplasms (6)  ·  Colonic Neoplasms (4)  ·  Rectal Neoplasms (3)  ·  Neoplasm Metastasis (2)  ·  Adenocarcinoma Of Esophagus (1)  ·  Carcinoma, Hepatocellular (1)  ·  Cold Hypersensitivity (1)  ·  Gastrointestinal Neoplasms (1)  ·  Neuralgia (1)  ·  Neuropathy, Painful (1)  ·  Pancreatic Neoplasms (1)  ·  Stomach Neoplasms (1)

Sponsors

Memorial Sloan Kettering Cancer Center (2)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  BinYong Liang (1)  ·  City of Hope Medical Center (1)  ·  Genentech, Inc. (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  Inspirna, Inc. (1)  ·  National Cancer Center Hospital East (1)  ·  Providence Health & Services (1)  ·  Washington University School of Medicine (1)

Countries

United States (7)  ·  France (1)  ·  Japan (1)

Top investigators

Nancy E. Kemeny, MD (2)  ·  Chia Portera, M.D. (1)  ·  Kohei Shitara, MD (1)  ·  Lily L. Lai, MD (1)  ·  Robert Wasserman, MD (1)  ·  Rom Leidner, MD (1)  ·  Simon Haroutounian, PhD (1)

Results publications

PMID 16009951, PMID 19233901, PMID 26032776, PMID 39863139

NIH funding

2017 (1), P30CA008748 (1), P30CA033572 (1)